RELATIONSHIP BETWEEN DNA PLOIDY AND SURVIVAL IN PATIENTS WITH EXOCRINE PANCREATIC-CANCER

被引：35

作者：

ESKELINEN, M

LIPPONEN, P

COLLAN, Y

MARIN, S

ALHAVA, E

NORDLING, S

机构：

[1] Departments of Surgery, University Central Hospital of Kuopio, Kuopio

[2] Departments of Pathology, University Central Hospital of Kuopio, Kuopio

[3] Department of Pathology, University of Turku, Turku

[4] Department of Pathology, University of Helsinki, Helsinki

来源：

PANCREAS | 1991年 / 6卷 / 01期

关键词：

DNA ploidy; Pancreatic cancer; Survival;

D O I：

10.1097/00006676-199101000-00012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The DNA ploidy of pancreatic cancer tissue from paraffin blocks was measured by flow cytometry in 46 patients whose disease had been detected and treated with surgery. Lymph node involvement was observed at the time of diagnosis in 36% of patients with diploid tumors and in 79% of patients with aneuploid tumors (p = 0.017), but no clear relation to metastasis could be observed (p = 0.201). The S-phase fraction (SPF) was significantly higher in aneuploid than in diploid tumors (p = 0.007). All patients who underwent radical surgery had diploid DNA content and SPF below the median (11.5%). Seven patients with a diploid tumor (32%) and none of the aneuploid cases survived 1 year. Over the 1-year period, in order of importance, the type of treatment (p < 0.001), DNA ploidy (p = 0.004), tumor size (p = 0.0046), and lymph node status (p = 0.027) predicted survival. Aneuploidy showed a significant association with decreased cumulative survival (p = 0.015), and a suggestive relationship with SPF was found. The results suggest that DNA ploidy of pancreatic cancer can be used in dividing the patients into different prognostic groups. The value of the detection of aneuploidy, however, is limited, because diploid pancreatic cancers are also generally rapidly fatal. © 1991 Raven Press, Ltd., New York.

引用

页码：90 / 95

页数：6

共 37 条

[1] Cubilla A.L., Fitzgerald P.J., Fortner J.G., Pancreas cancer, duct cell adenocarcinoma: Survival in relation to site, size, stage and type of therapy, J Surg Oncol, 10, pp. 465-482, (1978)
[2] Kummerle F., Ruckert K., Surgical treatment of pancreatic cancer, World J Surg, 8, pp. 889-894, (1984)
[3] Nix G., Schmitz P., Wilson J., Van Blankenstein M., Groeneveld C., Hofwijk R., Carcinoma of the head of the pancreas: Therapeutic implications of endoscopic retrograde cholangiopancreatography findings, Gastroenterology, 87, pp. 37-43, (1984)
[4] Nagai H., Kuroda A., Morioka Y., Lymphatic and local spread of Tl and T2 pancreatic cancer: A study of autopsy material, Ann Surg, 204, pp. 65-71, (1986)
[5] Cubilla A.L., Fitzgerald P.J., Tumors of the exocrine pancreas, Atlas of Tumor Pathology, Second Series, Fasc. 19, (1984)
[6] Kloppel G., Pancreatic non-endocrine tumours, Pancreatic Pathology, pp. 79-113, (1984)
[7] Andren-Sandberg A., Ihse I., Factors influencing survival after total pancreatectomy in patients with pancreatic cancer, Ann Surg, 198, pp. 605-610, (1983)
[8] Matsuno S., Sato S., Surgical treatment for carcinoma of the pancreas, Am J Surg, 152, pp. 499-504, (1986)
[9] Tsuchiya R., Tomioka T., Izawa K., Collective review of small carcinomas of the pancreas, Ann Surg, 203, pp. 77-84, (1986)
[10] Crist D.W., Sitzmann J.V., Cameron J.L., Improved hospital morbidity, mortality, and survival after the Whipple procedure, Ann Surg, 206, pp. 358-365, (1987)

← 1 2 3 4 →